肿瘤干细胞标志物CD133在鼻咽癌研究中的应用
|
摘要
临床研究发现肿瘤干细胞是多种肿瘤复发、转移及治疗失败的根源,肿瘤干细胞的研究对探寻鼻咽癌新的治疗手段意义重大,而准确识别特异性肿瘤标志物是进行临床研究的前提。CD133作为肿瘤干细胞标志物已被广泛应用于临床,在鼻咽癌肿瘤干细胞分选、鼻咽癌放疗抵抗、化疗耐药及预后等方面的研究也逐渐深入。全文就肿瘤干细胞概念、CD133基因、结构及其在鼻咽癌研究中的应用做一综述。
Clinical studies have found that cancer stem cells are the root cause of a variety of tumor recurrence,metastasis, and treatment failure. The study of cancer stem cells is of great significance for the exploration of new treatments for nasopharyngeal carcinoma, and accurate identification of specific tumor markers is a prerequisite for clinical research. As a marker of cancer stem cells, CD133 has been widely used in clinical research. Research on the selection of nasopharyngeal cancer stem cells, radiotherapy resistance, chemotherapeutic resistance, and prognosis of nasopharyngeal cancer is gradually deepening. This article reviews the concept of cancer stem cells, CD133 gene, structure and its application in nasopharyngeal carcinoma research.
Clinical studies have found that cancer stem cells are the root cause of a variety of tumor recurrence,metastasis, and treatment failure. The study of cancer stem cells is of great significance for the exploration of new treatments for nasopharyngeal carcinoma, and accurate identification of specific tumor markers is a prerequisite for clinical research. As a marker of cancer stem cells, CD133 has been widely used in clinical research. Research on the selection of nasopharyngeal cancer stem cells, radiotherapy resistance, chemotherapeutic resistance, and prognosis of nasopharyngeal cancer is gradually deepening. This article reviews the concept of cancer stem cells, CD133 gene, structure and its application in nasopharyngeal carcinoma research.
引文
[1] LO KW, TO KF, HUANG DP. Focus on nasopharyngeal carcinoma[J]. Cancer Cell, 2004, 5(5):423-428.
[2]李贤斌,吴海丽.鼻咽癌患者长期生存期的危险因素分析[J].西南国防医药, 2016, 26(6):646-648.
[3]易俊林,高黎,黄晓东. 416例鼻咽癌调强放疗远期生存与影响因素分析[J].中华放射肿瘤杂志, 2012, 21(3):196-197.
[4] MACKILLOP WJ, CIAMPI A, TILL JE, et al. A stem cell model of human tumor growth, implications for tumor cell clono-genic assays[J]. J Natl Cancer Inst, 1983, 70(1):9-16.
[5] SUGIHARA E, SAYA H. Complexity of cancer stem cells[J]. Cancer, 2013, 132(6):1249-1259.
[6] ROSHAL M, CHIEN S, OTHUS M, et al. The proportion of CD34+CD38(low or neg)myeloblasts, but not side population frequency,predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia[J]. Leukemia, 2013, 27(3):728-731.
[7] AI-HAJJ M, WICHA MS, BENITO HEMANDEZ A, et al. Prospective identification of tumorigenic breast cancer cell[J]. Proc Natl Acad Sci USA, 2003, 100(7):3983-3988.
[8] LI L, OSDAL T, HO Y, et al. SIRT1 Activation by a c-MYC oncogenic net-work promotes the maintenance and drug resistance of human FLT3ITD acute myeloid leukemia stem cell[J]. Cell Stem Cell,2014, 15(4):431-446.
[9] HO MM, NG AV, LAM S, et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells[J].Cancer Res, 2007, 67(10):4832-4833.
[10] LIAO WT, YE YP, DENG YJ, et al. Metastatic cancer stem cells:from the concept to therapeutics[J]. Am J stem Cell, 2014, 3(2):46-62.
[11] BARON M. An overview of the Notch signaling pathway[J]. Semin Cell Dev Biol, 2003, 14(2):113-119.
[12] GROSSE-GEHLING P, FARGEAS CA, DITTFELD C, et al. CD133as a biomarker for putative cancer stem in solid tumours:limitations,problems and challenges[J]. J Pathol, 2013, 229(3):355-378.
[13] FARGEAS CA, JOESTER A, MISSOL-KOLKA E, et al. Identification of novel Prominin-1/CD133 splice variants with alternative C-termini and their expression in epididymis and testis[J]. J Cell Sci,2004, 117(Pt 18):4301-4311.
[14] MIRAGLIA S, GODFREY W, YIN AH, et al. A novel five-trans-membrane hematopoietic stem cell antigen:isolation, chara-cterization,and molecular cloning[J]. Blood, 1997, 90(12):5013-5021.
[15] SINGH SK, CLARKE ID, TERASAKI M, et al. Identification of a cancer stem cell in human brain tumors[J]. Cancer Res, 2003, 63(18):5821-5828.
[16]陈斌,沈顺利,彭宝岗.微小RNA let-7a对CD133+肝癌干细胞增殖和转移的影响[J].中华细胞与干细胞杂志(电子版), 2015, 5(3):44-47.
[17]高远,冯军,吴灵芝,等. CD133+肺癌干细胞中基质金属蛋白酶9和缺氧诱导因子2α的表达及其病理学机制[J].中华医学杂志, 2015,95(32):2607-2611.
[18] NOMURA A, BANERJEE S, CHUGH R, et al. CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer[J]. Oncotarget, 2015, 6(10):8313-8322.
[19]席小龙,姜波健,俞继卫. HOTAIR在CD133阳性胃癌细胞中的表达及其作用研究[J].中国普外基础与临床杂志, 2015, 22(6):659-664.
[20]林国彪,姚平,张锡流.人鼻咽癌细胞株分选CD133+细胞实验研究[J].临床与实验病理学杂志, 2012, 28(8):899-902.
[21]王海丽,文忠,申聪香,等.人鼻咽癌CD133+干细胞的生物学特性及意义[J].中国组织工程研究, 2012, 16(6):1007-1010.
[22]江庆萍,谢思明,王爽,等.鼻咽癌干细胞标志物的检测意义[J].实用癌症杂志, 2014, 29(8):889-892.
[23]关小芳,文忠,申聪香,等.人鼻咽癌细胞株中类肿瘤干细胞的分离、培养及鉴定[J].解放军医学杂志, 2008, 33(12):1461-1464.
[24]蔡润茁,曾令达,李登辉,等.鼻咽癌组织中CD133的表达情况与放疗预后的关系研究[J].标记免疫分析与临床, 2018, 25(10):1476-1479.
[25]付汐,卢国英,李志辉,等.干细胞标记物CD133及CK19在鼻咽癌的表达及其临床意义[J].医学临床研究, 2014, 31(8):1485-1487.
[26]姜林鹤,宋云骏,刘运江,等. CD133在结直肠癌组织中的表达及其与患者预后关系的研究[J].临床和实验医学杂志, 2015, 14(9):723-725.
[27]杨柯柯,申聪香,文忠,等.人鼻咽癌CD133+干细胞对肿瘤多药耐药作用的研究[J].中华肿瘤防治杂志, 2013, 20(18):1385-1390.
[28]刘超群.人鼻咽癌细胞株中肿瘤干细胞分离鉴定方法及肿瘤多药耐药机制[J].中国医学物理学杂志, 2018, 35(8):956-961.
[29]刘双,唐敏,甘生敏,等. X射线增强CD133-鼻咽癌细胞干样能力的研究[J].免疫学杂志, 2016, 32(6):491-495.
[30]汤国辉,张志伟,黄卫国,等. miR-142-3p通过靶向CD133抑制鼻咽癌细胞和鼻咽癌干细胞生长的效果研究[J].中国全科医学,2017, 20(17):2085-2094.
[2]李贤斌,吴海丽.鼻咽癌患者长期生存期的危险因素分析[J].西南国防医药, 2016, 26(6):646-648.
[3]易俊林,高黎,黄晓东. 416例鼻咽癌调强放疗远期生存与影响因素分析[J].中华放射肿瘤杂志, 2012, 21(3):196-197.
[4] MACKILLOP WJ, CIAMPI A, TILL JE, et al. A stem cell model of human tumor growth, implications for tumor cell clono-genic assays[J]. J Natl Cancer Inst, 1983, 70(1):9-16.
[5] SUGIHARA E, SAYA H. Complexity of cancer stem cells[J]. Cancer, 2013, 132(6):1249-1259.
[6] ROSHAL M, CHIEN S, OTHUS M, et al. The proportion of CD34+CD38(low or neg)myeloblasts, but not side population frequency,predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia[J]. Leukemia, 2013, 27(3):728-731.
[7] AI-HAJJ M, WICHA MS, BENITO HEMANDEZ A, et al. Prospective identification of tumorigenic breast cancer cell[J]. Proc Natl Acad Sci USA, 2003, 100(7):3983-3988.
[8] LI L, OSDAL T, HO Y, et al. SIRT1 Activation by a c-MYC oncogenic net-work promotes the maintenance and drug resistance of human FLT3ITD acute myeloid leukemia stem cell[J]. Cell Stem Cell,2014, 15(4):431-446.
[9] HO MM, NG AV, LAM S, et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells[J].Cancer Res, 2007, 67(10):4832-4833.
[10] LIAO WT, YE YP, DENG YJ, et al. Metastatic cancer stem cells:from the concept to therapeutics[J]. Am J stem Cell, 2014, 3(2):46-62.
[11] BARON M. An overview of the Notch signaling pathway[J]. Semin Cell Dev Biol, 2003, 14(2):113-119.
[12] GROSSE-GEHLING P, FARGEAS CA, DITTFELD C, et al. CD133as a biomarker for putative cancer stem in solid tumours:limitations,problems and challenges[J]. J Pathol, 2013, 229(3):355-378.
[13] FARGEAS CA, JOESTER A, MISSOL-KOLKA E, et al. Identification of novel Prominin-1/CD133 splice variants with alternative C-termini and their expression in epididymis and testis[J]. J Cell Sci,2004, 117(Pt 18):4301-4311.
[14] MIRAGLIA S, GODFREY W, YIN AH, et al. A novel five-trans-membrane hematopoietic stem cell antigen:isolation, chara-cterization,and molecular cloning[J]. Blood, 1997, 90(12):5013-5021.
[15] SINGH SK, CLARKE ID, TERASAKI M, et al. Identification of a cancer stem cell in human brain tumors[J]. Cancer Res, 2003, 63(18):5821-5828.
[16]陈斌,沈顺利,彭宝岗.微小RNA let-7a对CD133+肝癌干细胞增殖和转移的影响[J].中华细胞与干细胞杂志(电子版), 2015, 5(3):44-47.
[17]高远,冯军,吴灵芝,等. CD133+肺癌干细胞中基质金属蛋白酶9和缺氧诱导因子2α的表达及其病理学机制[J].中华医学杂志, 2015,95(32):2607-2611.
[18] NOMURA A, BANERJEE S, CHUGH R, et al. CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer[J]. Oncotarget, 2015, 6(10):8313-8322.
[19]席小龙,姜波健,俞继卫. HOTAIR在CD133阳性胃癌细胞中的表达及其作用研究[J].中国普外基础与临床杂志, 2015, 22(6):659-664.
[20]林国彪,姚平,张锡流.人鼻咽癌细胞株分选CD133+细胞实验研究[J].临床与实验病理学杂志, 2012, 28(8):899-902.
[21]王海丽,文忠,申聪香,等.人鼻咽癌CD133+干细胞的生物学特性及意义[J].中国组织工程研究, 2012, 16(6):1007-1010.
[22]江庆萍,谢思明,王爽,等.鼻咽癌干细胞标志物的检测意义[J].实用癌症杂志, 2014, 29(8):889-892.
[23]关小芳,文忠,申聪香,等.人鼻咽癌细胞株中类肿瘤干细胞的分离、培养及鉴定[J].解放军医学杂志, 2008, 33(12):1461-1464.
[24]蔡润茁,曾令达,李登辉,等.鼻咽癌组织中CD133的表达情况与放疗预后的关系研究[J].标记免疫分析与临床, 2018, 25(10):1476-1479.
[25]付汐,卢国英,李志辉,等.干细胞标记物CD133及CK19在鼻咽癌的表达及其临床意义[J].医学临床研究, 2014, 31(8):1485-1487.
[26]姜林鹤,宋云骏,刘运江,等. CD133在结直肠癌组织中的表达及其与患者预后关系的研究[J].临床和实验医学杂志, 2015, 14(9):723-725.
[27]杨柯柯,申聪香,文忠,等.人鼻咽癌CD133+干细胞对肿瘤多药耐药作用的研究[J].中华肿瘤防治杂志, 2013, 20(18):1385-1390.
[28]刘超群.人鼻咽癌细胞株中肿瘤干细胞分离鉴定方法及肿瘤多药耐药机制[J].中国医学物理学杂志, 2018, 35(8):956-961.
[29]刘双,唐敏,甘生敏,等. X射线增强CD133-鼻咽癌细胞干样能力的研究[J].免疫学杂志, 2016, 32(6):491-495.
[30]汤国辉,张志伟,黄卫国,等. miR-142-3p通过靶向CD133抑制鼻咽癌细胞和鼻咽癌干细胞生长的效果研究[J].中国全科医学,2017, 20(17):2085-2094.